EDAP TMS France est membre de Lyonbiopôle

General information

4 rue du Dauphiné

69120 Vaulx-en-Velin

Incorporated in: 1994/05/06

Turnover: €41M (in 2020)

More information


Main activity

A global leader in therapeutic ultrasound, EDAP TMS is a high-tech medical company listed on the Nasdaq (EDAP). EDAP TMS develops, manufactures and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology. By strongly investing in R&D activities and partnering with renowned medical research institutions, EDAP TMS has maintained and strengthened its high level of innovation and research since its inception in 1979. Today’s development efforts are focused on making High Intensity Focused Ultrasound (HIFU) a standard therapy for soft tissue ablation. Based near Lyon-France, the company is actively operating worldwide with subsidiaries and offices in Austin (Texas, USA), Tokyo (Japan), Flensburg (Germany), Kuala Lumpur (Malaysia), Seoul (South Korea), Dubai (UAE) and Moscow (Russia), as well as through more than 70 distribution partners. The HIFU and ESWL divisions market products developed and manufactured by EDAP TMS for the treatment of Prostate Cancer and Urinary Stones. To complete EDAP’s product offering and drive additional growth, the distribution division markets third-party devices in the urology space.


Public funding obtained: FUI : 91 K€ / 3 years / 2013 FUI : 1,4 M€ / 3 years / 2011 OSEO : 300 K€ / 3 years /2008 ANR : 212 K€ / 3 years / 2010 OSEO : 65 K€ / 3 years /2008

Stock exchange listing: EDAP TMS SA (Holding) is listed on NASDAQ market in New York since 1997.

Products / Services / Technologies

Strategic area of application
Human Medicine

Application market

Medical device